Immunocine Cancer Center Appoints Johns Hopkins Veteran Dr. Stephen J. Noga as Chief Medical Officer to Advance Personalized Dendritic Cell Immunotherapy
核心洞察
Immunocine Cancer Center (搜索) has appointed Stephen J. Noga, M.D., Ph.D., a former Johns Hopkins faculty member with over three decades of oncology experience, as its new Chief Medical Officer.
Dr. Noga's early doctoral research contributed to the identification of dendritic cells, which are now central to Immunocine's personalized cancer immunotherapy platform.
In his new role, Dr. Noga will oversee medical operations and guide development of therapies that use a patient's own tumor tissue and dendritic cells to train the immune system against their cancer.
HOUSTON, TX — Immunocine Cancer Center (搜索) announced on August 10, 2026, the appointment of Stephen J. Noga, M.D., Ph.D., an internationally recognized medical oncologist, hematologist, and cellular therapy expert, as the company's new Chief Medical Officer. Dr. Noga, a former faculty member of the Johns Hopkins University School of Medicine, brings more than three decades of experience spanning academic medicine, cancer research, hematopoietic stem cell transplantation, cellular therapies, immunotherapy, and precision oncology.
In his new role, Dr. Noga will oversee medical and oncologic operations while helping guide the continued development of Immunocine's personalized immunotherapy programs. These programs utilize a patient's own tumor tissue and dendritic cells to help train the immune system to recognize and target that individual's cancer.
"The future of oncology lies in increasingly personalized treatment strategies," said Dr. Noga. "Every patient's cancer is unique, and advances in tumor biology and immunology are allowing us to develop therapies that are better tailored to each individual. Joining Immunocine is an opportunity to return to the scientific questions that first inspired my career and help translate decades of research into meaningful advances for cancer patients."
A Career Rooted in Dendritic Cell Discovery
Dr. Noga's scientific career began as a medical technologist at the University of Florida, where his interest in the hematopoietic system led him to pursue a Ph.D. in Experimental Pathology. His doctoral research helped demonstrate the existence of two distinct populations of blood monocytes, one of which would later become recognized as dendritic cells — immune cells now central to many modern cancer immunotherapy strategies.
Determined to translate those laboratory discoveries into patient care, Dr. Noga subsequently earned his medical degree, completed his residency and oncology fellowship at Johns Hopkins University, and joined the faculty, where he served for nearly two decades as Associate Professor of Oncology and Pathology. Following his tenure at Johns Hopkins, he served as Clinical Professor of Oncology at the University of Maryland Greenbaum Comprehensive Cancer Center, where he was the attending physician on the stem cell transplantation program.
Leadership Across Academia and Industry
Throughout his distinguished career, Dr. Noga has held leadership positions at Johns Hopkins Medicine, MedStar Health, Takeda Oncology, Exact Sciences (搜索), and other leading healthcare organizations. Most recently, he served as Senior Medical Director for Molecular Residual Disease at Exact Sciences and previously served as Vice President of U.S. Medical Affairs for Oncology at Takeda Oncology, where he helped lead national oncology initiatives, clinical strategy, and scientific engagement programs. He has authored hundreds of scientific publications.
Immunocine's Personalized Immunotherapy Platform
Immunocine Cancer Center (搜索) uses personalized dendritic cell-based immunotherapy approaches that incorporate tumor-specific information derived from a patient's own cancer tissue. Through the company's patented double-loading process, these therapies are designed to educate the immune system to recognize and respond more effectively to cancer cells while advancing individualized treatment strategies.
"Dr. Noga is uniquely qualified to help lead Immunocine because he brings together two perspectives that are rarely found in one individual," said Matt Halpert, Ph.D., Founder and Chief Executive Officer of Immunocine Cancer Center (搜索). "He is both a true Ph.D. scientist whose early research helped advance our understanding of dendritic cells and a highly accomplished medical oncologist who has spent decades caring for cancer patients and leading clinical innovation. The scientific questions he began exploring early in his career have now evolved into real-world personalized immunotherapy approaches that we use every day at Immunocine."
As Chief Medical Officer, Dr. Noga will also serve as a scientific spokesperson for the company, available to discuss personalized immunotherapy and precision oncology, dendritic cell therapy and cellular therapies, molecular diagnostics and individualized treatment strategies, tumor preservation and patient-specific cancer vaccines, emerging immune-based cancer therapies, and clinical trials and advances in oncology research.
Immunocine Cancer Center (搜索) operates treatment centers in Cancun and Cabo San Lucas, Mexico, serving patients from around the world seeking innovative immune-based cancer treatment options.